Description

Haemonetics Corporation: Initiation Of Coverage – A Tale Of Strategic Acquisitions & Synergies! 

Haemonetics Corporation showed positive financial results, with a third quarter revenue of $336 million, an impressive 10% growth on both reported and organic bases. Earnings per diluted share also grew by 22% compared with the previous year, which Haemonetics attributes to above-market growth and the successful achievement of important long range plan milestones. The conference call presentation highlighted the revenue increases across segments, with the plasma revenue growing by 8% in the third quarter and the Hospital business revenue growth skyrocketing by an impressive 22%.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!